A second House hearing will zero in on Johnson & Johnson's handling of quality problems affecting children's medicines and adult-strength Motrin. A key question centers on whether the company hushed-up recalls of affected products.
Read More...
Read the complete post at http://www.npr.org/blogs/health/2010/09/30/130235595/johnson-johnson-execs-face-more-questions-on-phantom-recall?ft=1&f=103537970
Posted
Sep 30 2010, 06:29 AM
by
NPR Blogs: Shots - Health News Blog